Summary We report the use of the steroidal aromatase inhibitor, 4-hydroxyandrostenedione (4-OHA, CGP 32349), in the management of patients with advanced, hormone resistant, prostatic cancer. Eighteen of 25 patients (72%) showed a subjective response, mainly in the form of pain relief and increased performance. There were no objective improvements. A tumour flare occurred in 17/25 (68%). Detailed endocrine studies were performed during treatment. These showed that suppression of serum oestradiol levels occurred in 19/25 (76%) of patients during treatment with 4-OHA. Serum levels of androstenedione increased in 9/14 patients (64%). Concentration of serum testosterone and 5 alpha-dihydrotestosterone were elevated in 3/14 (21%) and 2/11 (18%) patients respectively. There appeared to be no correlation between response or tumour flare and changes in steroid levels during treatment with 4-OHA.
The management of patients with advanced, hormone resistant prostatic cancer is difficult and consists mainly of palliation of symptoms (Lancet, 1980) . The life expectancy of this group of patients is limited (Parker et al., 1985) . Since 1987, we have investigated the possible place of aromatase inhibitors in the management of advanced prostate cancer. Aromatase (oestrogen synthetase) mediates the conversion of androgens to oestrogens and is a key enzyme in the steroidogenic pathway from cholesterol to oestrogens. Inhibition of aromatisation will not cause depletion of steroids more proximal in the steroidogenic pathway as it is the last reaction in oestrogen production (Brodie et al., 1977) . Worgul et al. (1983) first suggested that aromatase inhibition may be of benefit in patients with advanced hormone resistant prostatic cancer. This followed observations during the use of aminoglutethimide (Ag) in such patients where significant subjective response were observed (Robinson et al., 1980) . Endocrine studies subsequently showed that the clinical effect of Ag was not attributable to androgen suppression (Dowsett et al., 1988) . Ag is a potent aromatase inhibitor (Brodie et al., 1981a ) and it was therefore considered possible that this may be its mode of action. Ag has significant central side effects limiting its use. A more selective inhibitor was therefore needed to test this hypothesis.
We have previously reported our preliminary experience using the selective steroidal aromatase inhibitor (4-hydroxyandrostendione (4-OHA, CGP 32349) in the palliation of patients with advanced hormone resistant prostatic cancer (Shearer et al., 1990) . A significant proportion (63%) gained benefit, mainly in the form of pain relief. However, the mechanism of action of an aromatase inhibitor in such patients remained obscure. Oestradiol suppression was observed in five out of eight patients in which it was measured. A tumour 'flare' was observed in 31% of the patients observed. This was thought to possibly represent a biological response to aromatase inhibition although the cause of the flare was unknown. 
Assessment
All patients were clinically staged at entry into the study and at 3 and 6 months on treatment. Staging was performed using UICC, T and M criteria. Primary tumour size was assessed by trans-rectal ultrasound using a Bruel and Kjaer machine. Metastases were assessed by bone scan and radiographs. Haematological and biochemical investigations were performed at monthly clinical assessments as follows: haemo-globin, total red cell count, platelets and white cell count; liver function, blood sugar, acid and alkaline phosphatases electrolytes and prostate specific antigen (PSA).
Hormonal indices
Hormonal indices evaluated were: oestradiol (E2), dihydrotestosterone (DHT), androstenedione (A) and testosterone (T). The method used for hormone measurement has previously been published .
Blood was taken prior to and on days 1,2,3 and 7 after commencing treatment with 4-OHA. Blood was then taken at the monthly clinical assessments for endocrine measurements. Wherever possible, blood samples were taken at the same time of day on each occasion. This was assessed by reference to the ECOG scale as in the preliminary study (Shearer et al., 1990) at monthly intervals. A complete subjective response was defined as an ECOG score of 0 on 2 consecutive occasions at least 4 weeks apart and partial response as a reduction in ECOG score of greater than 50% (Ponder et al., 1984) . Each vial was reconstituted with 2 ml of saline before use. Dosage used was 500 mg as a single deep intra-muscular injection on a weekly basis administered by a research nurse at the patients home.
Results
Thirty patients were entered into the study. The age range was 59-87 years (average 72). All had ECOG scores of at least 9. Four had a baseline score of 10. Twenty seven (87%) patients were taking narcotic analgesics. All patients were noted to be taking some form of non-narcotic analgesic. All had bony metastases, the most common sites being lumbar spine, pelvis and ribs. None had soft tissue metastases. Twenty eight patients (90%) had undergone an orchidectomy as first-line treatment with a median duration of response of 12 months (range 2-43). Two patients received the LHRH analogue, Goserelin, as first line therapy. Twenty patients (65%) had received palliative radiotherapy before entry into the study either in the form of single fraction or hemi-body irradiation. Two had received steroids and one had been given Strontium 89.
Prior to entry into the study, all patients were noted to have low haemoglobin levels, indicative of the bone marrow disease usually present in such patients. All had raised alkaline and acid phosphatase levels representing extensive bony metastatic disease.
Five patients (16%) were inevaluable for the following reasons: One patient withdrew after the first treatment due to deciding not to continue to attend for follow up, two patients had not responded to first line endocrine therapy and were therefore excluded from the analysis, two patients were taking cyproterone acetate (anti-androgen) at the start of the study. The latter will be discussed further (see text). Side effects 4-OHA was generally well tolerated by patients. In two patients the dose was halved to 250 mg i.m. weekly due to pain at the site of the injection. Tumourflare Seventeen patients (68%) had a tumour flare, three (12%) severe. The flare took the form of an increase in bone pain, usually occurring 12-24 h after the first 4-OHA injection. In the majority of cases, this flare was mild and required a temporary increase in analgesia. The flare usually subsided within 24-48 h. Two patients entered the trial, but were subsequently excluded due to being on cyproterone acetate at the start of the study. One of these patients 
Discussion
The management of patients with advanced prostatic cancer who have failed first line endocrine manoeuvres, such as androgen deprivation, is difficult and is generally aimed at the palliation of symptoms, usually pain. The patients reported in this study all had heavily pre-treated end stage advanced prostate cancer. The quality of subjective response, in the form of increased performance and reduced pain relief, was impressive. The absence of objective responses is not surprising in this type of patient with widespread skeletal metastatic tumour burden.
The tumour flare observed in a high proportion of the patients in this study remains unexplained. The majority of patients demonstrated a fall in E2 during treatment but flare occurred in patients who did not demonstrate a fall in E2. 4-OHA is known to have weak androgenic properties (Brodie et al., 1977) and this may be responsible for the flare. The endocrine results indicate that, in some patients, small increases in T, DHT and A occurred on treatment with 4-OHA. The mechanism of this increase in androgen levels is unknown. No such changes have been noted in postmenopausal female patients with breast cancer but minor increases were noted in male volunteers with intact gonadal function treated with 4-OHA orally (Dowsett & Lloyd, 1990) . In this latter study it was postulated that a competition for catabolic routes of metabolism between 4-OHA and endogenous androgens may be the cause of the increase. There did not, however, appear to be any correlation with changes in androgens and those patients who experienced tumour flare. Cyproterone acetate did not influence the development or course of the flare. It is possible that one or more of the metabolites of 4-OHA are androgenic and responsible for the flare. 4-hydroxytestosterone is a know metabolite in rhesus monkeys treated with 4-OHA (Brodie et al., 1981b) but has not been demonstrated in humans. We examined the urine samples of two patients who experienced a tumour flare on 4-OHA by mass spectrometry and HPLC. 4-OHT was not detected (Poon et al., unpublished data) . 4 (Dowsett et al., 1988) . Ag is a potent aromatase inhibitor and therefore it seemed important to test a more selective aromatase inhibitor without the central nervous system side effects of AG. 4-OHA is a steroidal aromatase inhibitor which has been extensively investigated in the treatment of women with advanced breast cancer (Goss et al., 1984) . Much data have been accrued concerning the effects of such inhibitors in the female but little is known concerning their effects in man. Our preliminary study (Shearer et i that this may be responsible for the benefit observed. Oestrogens have attracted considerable interest in connection with prostatic biology particularly in the pathogenesis of benign prostatic hyperplasia (BPH) (Henderson et al., 1986) . Several lines of evidence suggest that oestrogens may be involved in the development of BPH (Matzkin et al., 1991) . Whether oestrogens play a role in the development and progression of prostatic carcinoma remains conjectural. We have conducted parallel laboratory studies which have shown that the aromatase enzyme does not appear to be present in either benign or malignant prostatic tissue in vitro (Davies et al., 1989) . It has been reported that 4-OHA inhibits human prostatic 5 a reductase (Zoppi et al., 1988) enzyme activity. However, we have found that this inhibition is very weak in human benign and malignant prostatic tissue in vitro (Davies et al., 1989) . This clinical study found no relationship between subjective response and oestradiol suppression. The mechanism of action of 4-OHA therefore remains unclear.
The beneficial effects of 4-OHA may be due to an action unrelated to its aromatase inhibitory activity. Inhibition of prostaglandin synthetase activity as a possible mode of action by AG in patients with prostate cancer (Harris et al., 1983) or a central action (Santen et al., 1981) has been suggested. Whether this is the case in patients treated with 4-OHA is unsubstantiated.
In conclusion, we have found 4-OHA to be effective in palliating patients with advanced prostate cancer who have failed all other palliative measures. The mechanism of action of 4-OHA in such patients may be by suppressing oestradiol, altering oestrogen related bone metabolism and hence reducing metastatic activity. Further work in this area would appear worthwhile and may lead to further understanding of the effects of oestrogens on prostatic biology and on metastatic prostate cancer.
